/PRNewswire/ The law firm of Kessler Topaz Meltzer & Check, LLP reminds Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") investors that the firm has.
Toll free (844) 887-9500
FibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease, and cancer. Its most advanced product is roxadustat ( Roxa ), an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase activity that acts by stimulating the body s natural pathway for red cell production.
The complaint alleges that throughout the Class Period, the defendants made false and/or misleading statements or failed to disclose that: (1) based on the safety data from FibroGen s two Phase 3 trials in China, any safety data obtained from the global Phase 3 trials would require post-hoc changes to the stratification factors to meet the U.S. Food and Drug Administration s ( FDA ) requirements; (2) FibroGen s disclosures of U.S. primary cardiovascular safety analyses from the Roxa global Phase 3 program for the treatmen
Share this article
Share this article
RADNOR, Pa., May 17, 2021 /PRNewswire/ The law firm of Kessler Topaz Meltzer & Check, LLP announces that the firm has filed a securities fraud class action against Emergent BioSolutions Inc. (NYSE: EBS) ( Emergent ) on behalf investors who purchased or acquired Emergent common stock
between April 24, 2020, and April 16, 2021, inclusive (the Class Period ). This action, captioned
Roth v. Emergent BioSolutions Inc., et al., Case No. 1:21-cv-01189-CCB (the
Roth Action ), was filed in the United States District Court for the District of Maryland (Southern Division). To view a copy of the
There is one related class action case pending against Emergent in the United States District Court for the District of Maryland (Southern Division), and a published notice in that action triggered the deadline of
/PRNewswire/ The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Credit.
Share this article
Share this article
RADNOR, Pa., May 17, 2021 /PRNewswire/ The law firm of Kessler Topaz Meltzer & Check, LLP reminds Romeo Power, Inc. ( Romeo ) (NYSE: RMO; RMO.WT) f/k/a RMG Acquisition Corp. ( RMG ) (NYSE: RMG; RMG.U; RMG.WS) investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Romeo securities
between October 5, 2020 and March 30, 2021, inclusive (the Class Period ).
Investor Deadline Reminder: Investors who purchased or acquired Romeo securities
during the Class Period may, no later than June 15, 2021, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; toll free at (844) 887-9500; via e-mail at[email protected];